Display options
Cite
Baptista BO, de Souza ABL, Riccio EKP, et al. Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas. Malar J. 2022;21(1):6doi: 10.1186/s12936-021-04020-6.
Baptista, B. O., de Souza, A. B. L., Riccio, E. K. P., Bianco-Junior, C., Totino, P. R. R., Martins da Silva, J. H., Theisen, M., Singh, S. K., Amoah, L. E., Ribeiro-Alves, M., Souza, R. M., Lima-Junior, J. C., Daniel-Ribeiro, C. T., & Pratt-Riccio, L. R. (2022). Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas. Malaria journal, 21(1), 6. https://doi.org/10.1186/s12936-021-04020-6
Baptista, Barbara Oliveira, et al. "Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas." Malaria journal vol. 21,1 (2022): 6. doi: https://doi.org/10.1186/s12936-021-04020-6
Baptista BO, de Souza ABL, Riccio EKP, Bianco-Junior C, Totino PRR, Martins da Silva JH, Theisen M, Singh SK, Amoah LE, Ribeiro-Alves M, Souza RM, Lima-Junior JC, Daniel-Ribeiro CT, Pratt-Riccio LR. Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas. Malar J. 2022 Jan 04;21(1):6. doi: 10.1186/s12936-021-04020-6. PMID: 34983540; PMCID: PMC8729018.
Copy Download .nbib Format: NLM
Share it on

Malar J. 2022 Jan 04;21(1):6. doi: 10.1186/s12936-021-04020-6.

Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas.

Malaria journal

Barbara Oliveira Baptista, Ana Beatriz Lopes de Souza, Evelyn Kety Pratt Riccio, Cesare Bianco-Junior, Paulo Renato Rivas Totino, João Hermínio Martins da Silva, Michael Theisen, Susheel Kumar Singh, Linda Eva Amoah, Marcelo Ribeiro-Alves, Rodrigo Medeiros Souza, Josué Costa Lima-Junior, Cláudio Tadeu Daniel-Ribeiro, Lilian Rose Pratt-Riccio

Affiliations

  1. Laboratório de Pesquisa em Malária, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil.
  2. Centro de Pesquisa, Diagnóstico e Treinamento em Malária, Fiocruz, Secretaria de Vigilância em Saúde, Ministério da Saúde, Brazil.
  3. Departamento de Bioinformática, Fiocruz, Ceará, Brazil.
  4. Centre for Medical Parasitology at Department of International Health, Immunology and Microbiology, University of Copenhagen and Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  5. Immunology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
  6. Laboratório de Pesquisa Clínica em DST e AIDS, Instituto Nacional de Infectologia Evandro Chagas, Fiocruz, Rio de Janeiro, Brazil.
  7. Laboratório de Doenças Infecciosas na Amazônia Ocidental, Universidade Federal do Acre, Acre, Brazil.
  8. Laboratório de Imunoparasitologia, IOC, Rio de Janeiro, Fiocruz, Brazil.
  9. Laboratório de Pesquisa em Malária, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil. [email protected].
  10. Centro de Pesquisa, Diagnóstico e Treinamento em Malária, Fiocruz, Secretaria de Vigilância em Saúde, Ministério da Saúde, Brazil. [email protected].

PMID: 34983540 PMCID: PMC8729018 DOI: 10.1186/s12936-021-04020-6

Abstract

BACKGROUND: The GMZ2.6c malaria vaccine candidate is a multi-stage Plasmodium falciparum chimeric protein which contains a fragment of the sexual-stage Pfs48/45-6C protein genetically fused to GMZ2, a fusion protein of GLURP and MSP-3, that has been shown to be well tolerated, safe and immunogenic in clinical trials performed in a malaria-endemic area of Africa. However, there is no data available on the antigenicity or immunogenicity of GMZ2.6c in humans. Considering that circulating parasites can be genetically distinct in different malaria-endemic areas and that host genetic factors can influence the immune response to vaccine antigens, it is important to verify the antigenicity, immunogenicity and the possibility of associated protection in individuals living in malaria-endemic areas with different epidemiological scenarios. Herein, the profile of antibody response against GMZ2.6c and its components (MSP-3, GLURP and Pfs48/45) in residents of the Brazilian Amazon naturally exposed to malaria, in areas with different levels of transmission, was evaluated.

METHODS: This study was performed using serum samples from 352 individuals from Cruzeiro do Sul and Mâncio Lima, in the state of Acre, and Guajará, in the state of Amazonas. Specific IgG, IgM, IgA and IgE antibodies and IgG subclasses were detected by Enzyme-Linked Immunosorbent Assay.

RESULTS: The results showed that GMZ2.6c protein was widely recognized by naturally acquired antibodies from individuals of the Brazilian endemic areas with different levels of transmission. The higher prevalence of individuals with antibodies against GMZ2.6c when compared to its individual components may suggest an additive effect of GLURP, MSP-3, and Pfs48/45 when inserted in a same construct. Furthermore, naturally malaria-exposed individuals predominantly had IgG1 and IgG3 cytophilic anti-GMZ2.6c antibodies, an important fact considering that the acquisition of anti-malaria protective immunity results from a delicate balance between cytophilic/non-cytophilic antibodies. Interestingly, anti-GMZ2.6c antibodies seem to increase with exposure to malaria infection and may contribute to parasite immunity.

CONCLUSIONS: The data showed that GMZ2.6c protein is widely recognized by naturally acquired antibodies from individuals living in malaria-endemic areas in Brazil and that these may contribute to parasite immunity. These data highlight the importance of GMZ2.6c as a candidate for an anti-malarial vaccine.

© 2021. The Author(s).

Keywords: Antibodies; GMZ2.6c; Immune response; Malaria; Plasmodium falciparum; Vaccine

References

  1. J Exp Med. 1995 Aug 1;182(2):409-18 - PubMed
  2. Nat Immunol. 2011 Jun;12(6):492-9 - PubMed
  3. J Infect Dis. 1996 Mar;173(3):765-9 - PubMed
  4. Clin Vaccine Immunol. 2006 Jul;13(7):810-3 - PubMed
  5. J Immunol. 2013 Feb 1;190(3):1038-47 - PubMed
  6. Parasite Immunol. 1996 Feb;18(2):103-9 - PubMed
  7. Cell. 2001 Jan 12;104(1):153-64 - PubMed
  8. Parasite Immunol. 1988 Mar;10(2):209-18 - PubMed
  9. Nat Rev Microbiol. 2010 Apr;8(4):272-80 - PubMed
  10. Mol Biochem Parasitol. 1994 Nov;68(1):53-67 - PubMed
  11. N Engl J Med. 2008 Dec 11;359(24):2619-20 - PubMed
  12. PLoS Pathog. 2010 May 20;6(5):e1000912 - PubMed
  13. Mol Biochem Parasitol. 1997 Dec 1;90(1):21-31 - PubMed
  14. Infect Immun. 2001 Feb;69(2):996-1001 - PubMed
  15. J Biol Chem. 2014 Feb 14;289(7):3856-68 - PubMed
  16. Am J Trop Med Hyg. 2005 Dec;73(6):1096-103 - PubMed
  17. J Immunol. 2009 Aug 1;183(3):2176-82 - PubMed
  18. Parasite Immunol. 1999 Jan;21(1):35-44 - PubMed
  19. Mem Inst Oswaldo Cruz. 2011 Aug;106 Suppl 1:34-43 - PubMed
  20. Malar J. 2005 Sep 29;4:48 - PubMed
  21. J Exp Med. 1982 Mar 1;155(3):734-48 - PubMed
  22. PLoS One. 2010 Nov 29;5(11):e14114 - PubMed
  23. Front Immunol. 2019 Mar 15;10:439 - PubMed
  24. Vaccine. 2016 Apr 27;34(19):2207-15 - PubMed
  25. J Immunol. 1990 Dec 1;145(11):3654-60 - PubMed
  26. Infect Immun. 2012 Jun;80(6):2240-6 - PubMed
  27. Am J Trop Med Hyg. 2017 Nov;97(5):1581-1592 - PubMed
  28. PLoS One. 2011;6(7):e22525 - PubMed
  29. Antimicrob Agents Chemother. 2015 Aug;59(8):4719-26 - PubMed
  30. Infect Immun. 1998 Jan;66(1):11-7 - PubMed
  31. Parasit Vectors. 2017 Aug 23;10(1):395 - PubMed
  32. Immunol Rev. 2019 Nov;292(1):139-148 - PubMed
  33. Nat Rev Immunol. 2009 Apr;9(4):235-45 - PubMed
  34. Methods Mol Biol. 1996;50:263-91 - PubMed
  35. Parasite Immunol. 2007 Jun;29(6):309-17 - PubMed
  36. Mem Inst Oswaldo Cruz. 1992;87 Suppl 3:229-34 - PubMed
  37. Malar J. 2013 Feb 05;12:51 - PubMed
  38. Mem Inst Oswaldo Cruz. 2013 Jun;108(4):523-8 - PubMed
  39. Vaccine. 2000 Sep 15;19(2-3):204-12 - PubMed
  40. Adv Immunol. 1993;54:229-70 - PubMed
  41. Trop Med Int Health. 2008 Feb;13(2):229-37 - PubMed
  42. Vaccine. 2009 Nov 16;27(49):6862-8 - PubMed
  43. Vaccine. 2010 Sep 24;28(41):6698-703 - PubMed
  44. Infect Immun. 2008 May;76(5):2240-8 - PubMed
  45. Med Microbiol Immunol. 2018 Aug;207(3-4):167-174 - PubMed
  46. PLoS One. 2011 Jan 14;6(1):e15983 - PubMed
  47. Mol Biochem Parasitol. 1991 Nov;49(1):119-31 - PubMed
  48. Malar J. 2016 Oct 21;15(1):517 - PubMed
  49. Parasite Immunol. 2003 Jun;25(6):307-12 - PubMed
  50. Am J Trop Med Hyg. 2002 May;66(5):509-15 - PubMed
  51. Int J Parasitol. 2004 Jul;34(8):935-42 - PubMed
  52. Malar J. 2012 Feb 15;11:46 - PubMed
  53. Infect Immun. 2008 Feb;76(2):759-66 - PubMed
  54. Parasite Immunol. 1990 Sep;12(5):447-56 - PubMed
  55. J Infect Dis. 2013 Aug 1;208(3):479-88 - PubMed
  56. Immunol Lett. 1999 Jan;65(1-2):29-33 - PubMed
  57. Immunology. 2010 Apr;129(4):474-81 - PubMed
  58. Am J Trop Med Hyg. 1998 Feb;58(2):211-9 - PubMed
  59. Am J Trop Med Hyg. 1998 Jun;58(6):768-74 - PubMed
  60. N Engl J Med. 2009 Jul 30;361(5):455-67 - PubMed
  61. Immunol Lett. 1994 Jul;41(2-3):115-20 - PubMed
  62. PLoS Med. 2007 Nov 13;4(11):e320 - PubMed
  63. Infect Immun. 1997 Jan;65(1):116-21 - PubMed
  64. Infect Immun. 2000 May;68(5):2617-20 - PubMed
  65. Annu Rev Immunol. 2002;20:165-96 - PubMed
  66. Microb Cell Fact. 2018 Apr 5;17(1):55 - PubMed
  67. Curr HIV/AIDS Rep. 2008 Feb;5(1):13-9 - PubMed
  68. Mol Biochem Parasitol. 1997 Aug;87(2):231-4 - PubMed
  69. FEBS J. 2017 Aug;284(16):2560-2568 - PubMed
  70. Clin Exp Immunol. 1997 Jul;109(1):84-9 - PubMed
  71. J Infect Dis. 2008 Feb 15;197(4):519-26 - PubMed
  72. Front Immunol. 2016 Jan 27;7:13 - PubMed
  73. Curr Opin Immunol. 1996 Apr;8(2):199-205 - PubMed
  74. Expert Rev Vaccines. 2017 Sep;16(9):907-917 - PubMed
  75. Blood. 1994 Sep 1;84(5):1594-602 - PubMed
  76. Malar J. 2017 Aug 1;16(1):306 - PubMed
  77. Elife. 2020 May 12;9: - PubMed
  78. PLoS One. 2009 Oct 27;4(10):e7590 - PubMed
  79. Mem Inst Oswaldo Cruz. 2013 Dec;108(8):968-73 - PubMed
  80. Infect Immun. 2006 Jan;74(1):257-64 - PubMed
  81. PLoS One. 2018 Aug 9;13(8):e0201669 - PubMed
  82. Vaccine. 2016 Aug 31;34(38):4536-4542 - PubMed
  83. Infect Immun. 2004 Jan;72(1):247-52 - PubMed

Publication Types

Grant support